Navigation Links
Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Date:7/23/2008

- Company Will Request Hearing to Present Plans for Regaining Compliance -

- NASDAQ Hearing Panel Has Discretion to Grant Peregrine Up to an

Additional 180 Days to Regain Compliance - - Peregrine Currently Meets All Other NASDAQ Capital Market Initial Listing

Requirements Other Than the $1.00 Minimum Bid Price Rule -

TUSTIN, Calif., July 23 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that it received a Staff Determination letter from the Nasdaq Stock Market (NASDAQ) on July 22, 2008 indicating that the company is not in compliance with the $1.00 minimum bid price requirement for continued listing set forth in NASDAQ Marketplace Rule 4310(c)(4). As a result, the company's common stock would be subject to delisting from the NASDAQ Capital Market unless Peregrine requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel"). Peregrine intends to request a hearing before the Panel, which will stay the delisting of the company's securities pending the Panel's decision. Rule 4805(a) provides that all hearings shall be scheduled, to the extent practicable, within 45 days of the date that the request for hearing is filed.

At the hearing, Peregrine intends to request continued listing on the NASDAQ Capital Market based upon its plan for regaining compliance with the minimum bid price requirement. Pursuant to NASDAQ Marketplace Rule 4802(b), the Panel has the authority to grant Peregrine up to an additional 180 days from the date of the Staff Determination letter of July 22, 2008 (i.e. January 19, 2009) to implement its plan of compliance, which could include a reverse stock split if the price has not exceeded $1.00 per share for 10 conse
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... REYKJAVIK, Iceland , June 3, 2015   ... genome to improve health worldwide, today announced that it ... to provide clinical interpretation of the whole genome sequences ... of the first phase of the 100,000 Genomes Project ... WuXi NextCODE will deploy its unique database ...
(Date:6/3/2015)... 2015 Marktech Optoelectronics is pleased to ... APD’s have an internal gain mechanism, fast time response, ... infrared region. These APD’s are recommended for applications that ... to overcome high pre-amp noise. In addition, Marktech APD's ... ideal for extreme low-level light detection and short pulse ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 GEA's ... , which is a standalone, fully-equipped laboratory unit that ... for limited productions in pilot plants. The Panther™ NS3006L ... its compact design allows for easy installation with simple ... products. This homogenizer can be used in many different ...
(Date:6/3/2015)... June 03, 2015 From smart street ... important part in enabling success in dealing with important ... technology leaders helped bring focus to the role and ... Photonics21 annual meeting last week in Brussels. ... event, held 28 and 29 May at the Hotel ...
Breaking Biology Technology:WuXi NextCODE Wins Genomics England Clinical Interpretation Tender in both Rare Disease and Cancer 2Marktech Introduces New Line of APDs 2GEA Announces the Panther™ NS3006L, a Self-Contained, Fully-Equipped Laboratory Homogenizer Well Suited for Pilot Plants 2Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 2Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 3
... taskforce of forest industry,stakeholders from Eastern Canada ... bio-related opportunities within the forestry sector across ... is comprised of regional government,industry, federal and ... has come together to better understand what,opportunities ...
... the Ferring Research,Infertility and Gynaecology GrAnt (FRIGGA) are ... & Embryology Congress. The two,winners of this new ... and the Universitair Ziekenhuis (UZ) Brussel, Centre for,Reproductive ... for their outstanding,proposals for fundamental research to help ...
... 7 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), ... officer (CEO), has announced his,intent to retire on December ... serve on the Board. Mr. Freiman is the former ... Mr. Freiman is retiring after 11 years of ...
Cached Biology Technology:Atlantica BioEnergy Task Force Unveiled 2Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) 2008 Winners Announced 2Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) 2008 Winners Announced 3Neurobiological Technologies' CEO to Retire on December 31, 2008 2
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... for alternative ,medicines, and luxury goods in Asian markets, ... being invested in enforcement, while events such as China,s ... problem. However, research in Conservation Letters ... the ,War on Drugs, as they lack a long-term ...
... of Visualized Experiments , published a modern approach to ... intriguing research questions facing scientists todaythe origin of life ... is comprised of a modern and simplified approach to ... Harold Urey in 1953. Their research evaluated the possibility ...
... air pollution blowing across the Pacific Ocean is often caused ... and Europe, according to findings by UC Irvine and other ... Academy of Sciences . The study is the first ... is from the production in China of cellphones, televisions and ...
Cached Biology News:A 21st century adaptation of the Miller-Urey origin of life experiments 2Made in China for us: Air pollution tied to exports 2
PGF1α-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGF1α by GC- or LC-mass spectrometry....
...
Antibodies were affinity purified using epitopes specific to PPP1CC immobilized on solid support....
ANTI GELSOLIN...
Biology Products: